Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults

Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults

Background. Older and sicker adults with type 2 diabetes (T2D) were underrepresented in randomized trials of glucagon-like peptide 1 receptor-agonist (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2I), and thus, health benefits are uncertain in this population. Objective. To assess the...

Full description

Bibliographic Details
Main Authors:	Rahul S. Dadwani, Wen Wan, M. Reza Skandari, Elbert S. Huang
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-07-01
Series:	MDM Policy & Practice
Online Access:	https://doi.org/10.1177/23814683231187566

Similar Items

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
by: Apurva Khedagi, et al.
Published: (2023-03-01)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
by: Soraya Puglisi, et al.
Published: (2021-10-01)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
by: Dario Giugliano, et al.
Published: (2021-10-01)

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
by: Agata Winiarska, et al.
Published: (2021-10-01)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
by: Panagiotis I. Georgianos, et al.
Published: (2022-02-01)

An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
by: Mustafa Kılıçkap, et al.
Published: (2021-02-01)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
by: Vikas S. Sridhar, et al.
Published: (2020-09-01)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
by: Bartosz Rolek, et al.
Published: (2023-07-01)

Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
by: Veronika A. Myasoedova, et al.
Published: (2023-12-01)

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
by: Suzanne V. Arnold, et al.
Published: (2022-04-01)

SGLT2 Inhibitors and GLP-1 Agonists: A Beacon of Hope for Stroke Prevention in Diabetes
by: Jae-Han Jeon
Published: (2024-03-01)

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
by: Marta Baviera, et al.
Published: (2022-08-01)

Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
by: Omar Dzaye, et al.
Published: (2022-07-01)

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
by: Gurgle HE, et al.
Published: (2016-06-01)

Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment
by: Khary Edwards, et al.
Published: (2023-06-01)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
by: Dario Giugliano, et al.
Published: (2022-03-01)

Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review
by: Katherine G. Young, et al.
Published: (2023-10-01)

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
by: Kazushi Uneda, et al.
Published: (2021-05-01)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
by: Jimmy Gonzalez, et al.
Published: (2023-03-01)

Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
by: Nicholas E. King, et al.
Published: (2022-01-01)

Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
by: André J. Scheen
Published: (2024-01-01)

SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study
by: Zheer Kejlberg Al-Mashhadi, et al.
Published: (2022-08-01)

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
by: Moa Lugner, et al.
Published: (2021-03-01)

Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
by: Dion R. P. Muller, et al.
Published: (2023-10-01)

Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study
by: Yoshimi Muta, et al.
Published: (2024-03-01)

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
by: Chen Li, et al.
Published: (2022-02-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
by: Heeyoung Lee, et al.
Published: (2021-09-01)

GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes
by: Raffaele Marfella, et al.
Published: (2024-01-01)

GLP-1 Receptor Agonists and Kidney Protection
by: Eulalia Valentina Greco, et al.
Published: (2019-05-01)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
by: Xin Zhao, et al.
Published: (2021-08-01)

Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
by: Hong Ma, et al.
Published: (2023-03-01)

Benefits of SGLT2 inhibitors in arrhythmias
by: Jinghan Gao, et al.
Published: (2022-10-01)

Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
by: Susanne B. Nicholas, et al.
Published: (2023-01-01)

Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study
by: Minji Sohn, et al.
Published: (2023-06-01)

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
by: Karen Schneck, et al.
Published: (2024-03-01)

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
by: Sara Piccini, et al.
Published: (2023-03-01)

Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients
by: Yang Lu, et al.
Published: (2023-06-01)

Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management
by: Sanjay Kalra, et al.
Published: (2022-05-01)

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
by: Pierre Gourdy, et al.
Published: (2023-04-01)